DiagnosTear Technologies Inc. is a health technology company specializing in advanced ophthalmic diagnostics. The company focuses on developing and commercializing innovative solutions aimed at enhancing the detection and management of various eye diseases. Its core offerings include the TeaRx Dry Eye test, a CE-IVD approved assay designed to identify and monitor Dry Eye Syndrome; the TeaRx Red Eye, which enables differential assessment of conditions such as adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis; and the TeaRx Tear Collector, a proprietary microfluidic device for non-invasive tear collection to support downstream analyses. Established in 2023 and headquartered in Vancouver, DiagnosTear Technologies serves a critical need within the medical specialties sector, helping eye care professionals better diagnose and manage ocular conditions. The company is positioned at the intersection of medical innovation and clinical application, contributing to advancements in ophthalmic care by providing more precise and accessible diagnostic tools.